Lantern Pharma Receives FDA Guidance for Pediatric CNS Cancer Trial Following Successful Type C Meeting

Lantern Pharma (NASDAQ: LTRN), an AI-driven clinical-stage oncology company, has successfully completed a Type C meeting with the U.S. Food and Drug Administration, marking a significant regulatory milestone for its pediatric central nervous system cancer program. The FDA provided comprehensive guidance on the regulatory pathway and trial design for the planned pediatric study targeting CNS cancers, including Atypical Teratoid Rhabdoid Tumor (ATRT), a rare and aggressive form of pediatric brain cancer.

The regulatory agency supported Lantern's proposal for a parallel ATRT cohort and endorsed the potential inclusion of spironolactone as a combination agent with LP-184/STAR-001, the company's lead investigational therapy. This FDA guidance provides crucial regulatory clarity that will help streamline the development pathway for this promising treatment approach. Through its subsidiary Starlight Therapeutics, Lantern will submit an Investigational New Drug (IND) amendment reflecting the FDA's feedback, with trial initiation targeted for the first quarter of 2026.

The program holds both Rare Pediatric Disease and Orphan Drug designations from the FDA, recognizing the significant unmet medical need in pediatric CNS cancers and providing certain development incentives. The planned multi-site clinical study will focus on key efficacy endpoints including progression-free survival, overall response rate, and quality-of-life outcomes, addressing both survival and functional aspects of treatment for pediatric patients.

This development represents an important advancement in pediatric oncology, particularly for ATRT and other CNS cancers that have limited treatment options and poor prognoses. The use of Lantern's proprietary AI and machine learning platform, RADR®, which leverages over 200 billion oncology-focused data points, has been instrumental in accelerating the identification and development of this therapeutic approach. The successful FDA meeting outcome demonstrates the potential of AI-driven drug development to address complex medical challenges more efficiently.

The implications of this regulatory progress extend beyond the immediate patient population, potentially establishing new paradigms for combination therapy approaches in pediatric oncology. For investors and the broader oncology community, this milestone underscores Lantern Pharma's ability to navigate complex regulatory landscapes and advance innovative cancer therapies. Additional information about the company's developments is available through its newsroom at https://ibn.fm/LTRN.